OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine

Lipton, Richard B.; Varon, SF; Grosberg, Brian M.; McAllister, Peter; Freitag, Fred; Aurora, SK; Dodick, David W.; Silberstein, Stephen D.; Diener, Hans-Christoph; DeGryse, Ronald; Nolan, Marissa E.; Turkel, Catherine C.

doi:10.1212/wnl.0b013e318232ab65

Cited by 132 publications

(111 citation statements)

References 35 publications

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…This study may further support the role of a peripheral mechanism in the complex migraine cascade. Botulinum toxin-A (Botox) injections have been recognized and Food and Drug Administration-approved as an effective temporary preventative therapy for chronic migraine headaches, [15][16][17] and surgical decompression or neurectomy of select injection sites has been used to achieve long-term improvement of patients with diagnosed peripheral nerve compression. [6][7][8][9][10][11][12][13] …”

mentioning

confidence: 99%

A Review of Current Evidence in the Surgical Treatment of Migraine Headaches

Janis¹,

Barker²,

Javadi³

et al. 2014

Plastic and Reconstructive Surgery

107

123

View full text Add to dashboard Cite

Migraines affect 18% of women and 6% of men and result in an estimated $1 billion in medical costs and $16 billion productivity loss in the United States annually. Migraine headaches persist as a problem of this scale because pharmacologic treatments for migraines are frequently incompletely effective, resulting in a population of patients with significant residual disability. In the last decade, novel approaches to the treatment of migraines have been developed based on the theory that extracranial sensory branches of the trigeminal and cervical spinal nerves can be irritated, entrapped, or compressed at points throughout their anatomic course, ultimately leading to the cascade of physiologic events that results in migraine. Botulinum toxin (Botox) injection and surgical decompression of these trigger points have been shown to reduce or eliminate migraines in patients who are incompletely treated by traditional medical management. Despite the recent advances made with Botox, this treatment strategy most commonly results in only temporary migraine prevention. However, the evidence supporting the efficacy and safety of permanent surgical decompression of peripheral trigger points is accumulating rapidly, and the overall success rate of surgery has approached 90%. In addition, an abundance of literature investigating the precise anatomical dissections associated with trigger points has been published concurrently. This article reviews the most up-to-date clinical and anatomic evidence available and seeks to provide a comprehensive, concise resource for the current state of the art in the surgical treatment of migraine headaches.

show abstract

mentioning

confidence: 99%

A Review of Current Evidence in the Surgical Treatment of Migraine Headaches

Janis¹,

Barker²,

Javadi³

et al. 2014

Plastic and Reconstructive Surgery

107

123

View full text Add to dashboard Cite

show abstract

“…Nearly 4 million people have had onobotulinum toxin A injections for headache. Onobotulinum toxin A has been found to significantly improve quality of life and reduce headache impact [7].…”

Section: First-line Preventive Medications For Migrainementioning

confidence: 99%

Migraine and Headache: General

Robbins

2015

Advanced Headache Therapy

View full text Add to dashboard Cite

“…They also demonstrated significant reductions in several other measures of migraine symptomology such as cumulative hours of headaches, headache days, and days of moderate/severe headaches [9]. Further studies indicated efficacy in reducing disease burden based on patient quality of life questionnaires [10,11]. However, studies evaluating the effect of BTX-A on episodic migraines so far have not shown significant benefits [12][13][14][15].…”

Section: Introductionmentioning

confidence: 99%

“…Over time, a number of well-designed large-scale studies demonstrated that this neurotoxin to be effective in reducing several measures of migraine symptomology [5][6][7][8][9][10][11]. The first major landmark study, called the PREEMPT (Phase III Research Evaluating Migraine Prophylaxis Therapy) trials, indicated that BTX-A is indeed effective and safe in treating migraine headaches.…”

Section: Introductionmentioning

confidence: 99%

Management of Migraine Headaches: OnabotulinumtoxinA Injection

Chung¹,

Li²,

Sanniec³

et al. 2017

Current Perspectives on Less-Known Aspects of Headache

View full text Add to dashboard Cite

Chronic migraines are a common debilitating headache disorder. Recently, there has been increasing interest in the use of onabotulinumtoxinA as a preventative treatment, as studies have shown significant benefits. In line with current accepted theories on the pathophysiology of migraines, the toxin works by both direct and indirect means to prevent peripheral and central nerve sensitization. While efficacy has been established, the technique for extracranial delivery of onabotulinumtoxinA continues to see changes in an effort to seek better outcomes. The PREEMPT injection protocol is the original injection paradigm design targeting broad muscle groups. The ART injection paradigm offers the ability to deliver onabotulinumtoxinA closer to culprit nerves, thus increasing its effect and also decreasing adverse effects. OnabotulinumtoxinA is an effective and well-tolerated option for selective patients seeking relief from migraine headaches.

show abstract

OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine

Abstract: This study provides Class 1A evidence that onabotulinumtoxinA treatment reduces headache impact and improves HRQoL.

Cited by 132 publications

References 35 publications

A Review of Current Evidence in the Surgical Treatment of Migraine Headaches

A Review of Current Evidence in the Surgical Treatment of Migraine Headaches

Migraine and Headache: General

Management of Migraine Headaches: OnabotulinumtoxinA Injection

Contact Info

Product

Resources

About